Clinical stable systemic mastocytosis with interferon alpha-2b therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10497631.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic mastocytosis (SM) with progressive infiltration of various organs by mast cells is a rare disease with a mean survival of 2 years. So far there is no established therapy. We describe a patient with progressive mastocytosis who had a clinical response to interferon alpha-2b 3 x 5 Mio U s.c. three times a week. The response is stable 3 years after initiation of therapy and includes reduction of abdominal lymphadenopathy, ascites, decrease of serum and urinary histamine levels as well as pulmonary reticulonodular markings.
Medical subject headings
- Antineoplastic Agents
- Glucocorticoids
- Interferon-alpha
- Mastocytosis
- Prednisone